Vaxine Ebola vaccine

Vaxine Pty Ltd's Ebola vaccine is an investigational vaccine candidate designed to prevent Ebola virus disease (EVD). Developed by the Australian biotechnology company Vaxine, the vaccine typically utilizes a recombinant protein subunit platform, focusing on the Ebola virus glycoprotein (GP) as the primary antigen. A distinguishing feature of Vaxine's vaccine candidates is the incorporation of Advax, a proprietary adjuvant derived from delta-inulin. Advax is engineered to enhance both humoral and cellular immune responses, promoting high-titer neutralizing antibodies and robust T-cell activity, while maintaining a favorable safety profile by minimizing the inflammatory side effects often associated with traditional adjuvants. The project is part of Vaxine's broader pipeline of Advax-adjuvanted vaccines targeting various infectious diseases.

Other names

ebola vaccine-Vaxine Pty Ltd-vaccine-Ebola